All Stories

  1. Current and Future Use of Long Axial Field-of-View Positron Emission Tomography/Computed Tomography Scanners in Clinical Oncology
  2. Precision estimates of relative and absolute cerebral blood flow in Alzheimer’s disease and cognitively normal individuals
  3. The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification
  4. Whole-Body Macrophage Positron Emission Tomography Imaging for Disease Activity Assessment in Early Rheumatoid Arthritis
  5. The approval of a disease-modifying treatment for Alzheimer’s disease: impact and consequences for the nuclear medicine community
  6. Houdini’s Illusions: Some Acts Are Not What They Seem to Be
  7. Education, training and registration of Medical Physics Experts across Europe
  8. Test-Retest Variability of Relative Tracer Delivery Rate as Measured by [11C]PiB
  9. [11C]PIB amyloid quantification: effect of reference region selection
  10. Tracer Kinetic Modelling
  11. Repeatability of parametric methods for [18F]florbetapir imaging in Alzheimer’s disease and healthy controls: A test–retest study
  12. Direct comparison of [11C] choline and [18F] FET PET to detect glioma infiltration: a diagnostic accuracy study in eight patients
  13. Quantitative parametric maps of O-(2-[18F]fluoroethyl)-L-tyrosine kinetics in diffuse glioma
  14. Association of amyloid pathology with memory performance and cognitive complaints in cognitively normal older adults: a monozygotic twin study
  15. Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies
  16. Diagnostic Value of Transluminal Attenuation Gradient for the Presence of Ischemia as Defined by Fractional Flow Reserve and Quantitative Positron Emission Tomography
  17. Improving metabolic stability of fluorine-18 labeled verapamil analogs
  18. Prophylactic and therapeutic activity of alkaline phosphatase in arthritic rats: single-agent effects of alkaline phosphatase and synergistic effects in combination with methotrexate
  19. A novel partial volume correction method for accurate quantification of [18F] flortaucipir in the hippocampus
  20. Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results
  21. The EMIF-AD PreclinAD study: study design and baseline cohort overview
  22. Quantification of O-(2-[18F]fluoroethyl)-L-tyrosine kinetics in glioma
  23. First in human evaluation of [18F]PK-209, a PET ligand for the ion channel binding site of NMDA receptors
  24. Quantification of [18F]florbetapir: A test–retest tracer kinetic modelling study
  25. In vivo evaluation of two tissue transglutaminase PET tracers in an orthotopic tumour xenograft model
  26. Identification of the allosteric P2X7 receptor antagonist [11C]SMW139 as a PET tracer of microglial activation
  27. [18F]NaF PET/CT scan as an early marker of heterotopic ossification in fibrodysplasia ossificans progressiva
  28. An exploratory clinical study of p38α kinase inhibition in Alzheimer's disease
  29. Automated SPECT analysis compared with expert visual scoring for the detection of FFR-defined coronary artery disease
  30. Bone formation in ankylosing spondylitis during anti-tumour necrosis factor therapy imaged by 18F-fluoride positron emission tomography
  31. Effect of Plaque Burden and Morphology on Myocardial Blood Flow and Fractional Flow Reserve
  32. Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody
  33. Bone formation in ankylosing spondylitis during anti-tumour necrosis factor therapy imaged by 18F-fluoride positron emission tomography
  34. Imaging and Methotrexate Response Monitoring of Systemic Inflammation in Arthritic Rats Employing the Macrophage PET Tracer [18F]Fluoro-PEG-Folate
  35. Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease
  36. Quantification of Tau Load in Alzheimer’s Disease Clinical Trials Using Positron Emission Tomography
  37. Model selection criteria for dynamic brain PET studies
  38. Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood–Brain Barrier Using Elacridar and 11C-Erlotinib PET
  39. Comparison of Coronary CT Angiography, SPECT, PET, and Hybrid Imaging for Diagnosis of Ischemic Heart Disease Determined by Fractional Flow Reserve
  40. Radiosynthesis of 1-iodo-2-[11 C]methylpropane and 2-methyl-1-[11 C]propanol and its application for alkylation reactions and C―C bond formation
  41. Comparison of In Vitro Assays in Selecting Radiotracers for In Vivo P-Glycoprotein PET Imaging
  42. Semi-quantitative cerebral blood flow parameters derived from non-invasive [15O]H2O PET studies
  43. Synthesis, radiolabeling and preclinical evaluation of a [ 11 C]GMOM derivative as PET radiotracer for the ion channel of the N-methyl-D-aspartate receptor
  44. Synthesis and Evaluation of New Fluorine-18 Labeled Verapamil Analogs To Investigate the Function of P-Glycoprotein in the Blood–Brain Barrier
  45. Effects of successful percutaneous coronary intervention of chronic total occlusions on myocardial perfusion and left ventricular function
  46. In-vivo monitoring of anti-folate therapy in arthritic rats using [18F]fluoro-PEG-folate and positron emission tomography
  47. Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine
  48. Forward to the Past: The Case for Quantitative PET Imaging
  49. Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET
  50. Disease Stage–Dependent Changes in Cardiac Contractile Performance and Oxygen Utilization Underlie Reduced Myocardial Efficiency in Human Inherited Hypertrophic Cardiomyopathy
  51. Cerebral rituximab uptake in multiple sclerosis: A 89Zr-immunoPET pilot study
  52. Partial volume correction of brain PET studies using iterative deconvolution in combination with HYPR denoising
  53. Quantification of Tau Load Using [18F]AV1451 PET
  54. A multi species evaluation of the radiation dosimetry of [ 11 C]erlotinib, the radiolabeled analog of a clinically utilized tyrosine kinase inhibitor
  55. Human Dosimetry of the N-Methyl-d-Aspartate Receptor Ligand 11C-GMOM
  56. Diagnostic impact of [18F]flutemetamol PET in early-onset dementia
  57. Development of fluorine-18 labeled peptidic PET tracers for imaging active tissue transglutaminase
  58. Erratum to: The need of standardization and of large clinical studies in an emerging indication of [18 F]FDG PET: the autoimmune encephalitis
  59. The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis
  60. Measurement of LV Volumes and Function Using Oxygen-15 Water-Gated PET and Comparison With CMR Imaging
  61. Parametric Methods for Dynamic 11C-Phenytoin PET Studies
  62. Prevalence of ischaemia in patients with a chronic total occlusion and preserved left ventricular ejection fraction
  63. Guidelines to PET measurements of the target occupancy in the brain for drug development
  64. Synthesis, radiolabeling and evaluation of novel amine guanidine derivatives as potential positron emission tomography tracers for the ion channel of the N-methyl-d-aspartate receptor
  65. Evaluation of myocardial blood flow and coronary flow reserve after implantation of a bioresorbable vascular scaffold versus metal drug-eluting stent: an interim one-month analysis of the VANISH trial
  66. Altered GABAA receptor density and unaltered blood–brain barrier [11C]flumazenil transport in drug-resistant epilepsy patients with mesial temporal sclerosis
  67. An automatic delineation method for bone marrow absorbed dose estimation in 89Zr PET/CT studies
  68. Strategies towards in vivo imaging of active transglutaminase type 2 using positron emission tomography
  69. Parametric Binding Images of the TSPO Ligand 18F-DPA-714
  70. Noninvasive Quantification of Myocardial 11C-Meta-Hydroxyephedrine Kinetics
  71. Development of carbon-11 labeled acryl amides for selective PET imaging of active tissue transglutaminase
  72. Imaging of neuroinflammation in Alzheimer's disease, multiple sclerosis and stroke: Recent developments in positron emission tomography
  73. Quantitative agreement between [15O]H2O PET and model free QUASAR MRI-derived cerebral blood flow and arterial blood volume
  74. Effects of erlotinib therapy on [11C]erlotinib uptake in EGFR mutated, advanced NSCLC
  75. Quantitative and Simplified Analysis of 11C-Erlotinib Studies
  76. Non-invasive imaging to identify susceptibility for ventricular arrhythmias in ischaemic left ventricular dysfunction
  77. In vivo assessment of myocardial viability after acute myocardial infarction: A head-to-head comparison of the perfusable tissue index by PET and delayed contrast-enhanced CMR
  78. The Association of Glucose Metabolism and Eigenvector Centrality in Alzheimer's Disease
  79. Impact of New Scatter Correction Strategies on High-Resolution Research Tomograph Brain PET Studies
  80. Repeatability of Quantitative 18F-Fluoromethylcholine PET/CT Studies in Prostate Cancer
  81. Multiparametric Analysis of the Relationship Between Tumor Hypoxia and Perfusion with 18F-Fluoroazomycin Arabinoside and 15O-H2O PET
  82. Myocardial denervation coincides with scar heterogeneity in ischemic cardiomyopathy: A PET and CMR study
  83. Imaging of neuroinflammation: TSPO and beyond
  84. Quantification of the novel N-methyl-d-aspartate receptor ligand [11C]GMOM in man
  85. Reply: Simplified Methods for Quantification of 18F-Fluoromethylcholine Uptake: Is SUVAUC,PP Actually an SUV?
  86. Incremental diagnostic value of epicardial adipose tissue for the detection of functionally relevant coronary artery disease
  87. Quantification of 11C-Laniquidar Kinetics in the Brain
  88. Coronary vasomotor function in infarcted and remote myocardium after primary percutaneous coronary intervention
  89. Use of a Single 11C-Meta-Hydroxyephedrine Scan for Assessing Flow–Innervation Mismatches in Patients with Ischemic Cardiomyopathy
  90. Quantification of Dynamic 11C-Phenytoin PET Studies
  91. A Cochrane review on brain [18F]FDG PET in dementia: limitations and future perspectives
  92. The impact of obesity on the relationship between epicardial adipose tissue, left ventricular mass and coronary microvascular function
  93. Prevalence of Amyloid PET Positivity in Dementia Syndromes
  94. Cerebral perfusion and glucose metabolism in Alzheimer’s disease and frontotemporal dementia: two sides of the same coin?
  95. Comparison of Velocity- and Acceleration-Selective Arterial Spin Labeling with [15O]H2O Positron Emission Tomography
  96. Doppler-Derived Intracoronary Physiology Indices Predict the Occurrence of Microvascular Injury and Microvascular Perfusion Deficits After Angiographically Successful Primary Percutaneous Coronary Intervention
  97. Synthesis, structure activity relationship, radiolabeling and preclinical evaluation of high affinity ligands for the ion channel of the N-methyl-d-aspartate receptor as potential imaging probes for positron emission tomography
  98. Sympathetic denervation is associated with microvascular dysfunction in non-infarcted myocardium in patients with cardiomyopathy
  99. A Clinical and Experimental Comparison of Time of Flight PET/MRI and PET/CT Systems
  100. Myocardial efficiency is an important determinant of functional improvement after aortic valve replacement in aortic valve stenosis patients: a combined PET and CMR study
  101. Quantification of 18F-Fluorocholine Kinetics in Patients with Prostate Cancer
  102. Radiopharmaceuticals for assessing ABC transporters at the blood-brain barrier
  103. Quantification of [18F]DPA-714 Binding in the Human Brain: Initial Studies in Healthy Controls and Alzheimer'S Disease Patients
  104. PET/CT-Derived Whole-Body and Bone Marrow Dosimetry of 89Zr-Cetuximab
  105. Neurophysiological Effects of Sleep Deprivation in Healthy Adults, a Pilot Study
  106. Sustained Macrophage Infiltration upon Multiple Intra-Articular Injections: An Improved Rat Model of Rheumatoid Arthritis for PET Guided Therapy Evaluation
  107. Relative Flow Reserve Derived From Quantitative Perfusion Imaging May Not Outperform Stress Myocardial Blood Flow for Identification of Hemodynamically Significant Coronary Artery Disease
  108. Nuclear medicine innovations help (drive) healthcare (benefits)
  109. Parametric Methods for Quantification of 18F-FAZA Kinetics in Non–Small Cell Lung Cancer Patients
  110. (R)-[11C]PK11195 brain uptake as a biomarker of inflammation and antiepileptic drug resistance: Evaluation in a rat epilepsy model
  111. Quantitative Assessment of Myocardial Perfusion in the Detection of Significant Coronary Artery Disease
  112. Quantification of [11C]-meta-hydroxyephedrine uptake in human myocardium
  113. Molecular imaging of targeted therapies with positron emission tomography: the visualization of personalized cancer care
  114. Validation of simplified dosimetry approaches in 89 Zr-PET/CT: The use of manual versus semi-automatic delineation methods to estimate organ absorbed doses
  115. Synthesis and preclinical evaluation of carbon-11 labelled N-((5-(4-fluoro-2-[11C]methoxyphenyl)pyridin-3-yl)methyl)cyclopentanamine as a PET tracer for NR2B subunit-containing NMDA receptors
  116. The Dopamine Stabilizer (−)-OSU6162 Occupies a Subpopulation of Striatal Dopamine D2/D3 Receptors: An [11C]Raclopride PET Study in Healthy Human Subjects
  117. The need for quantitative PET in multicentre studies
  118. Comparison of HRRT and HR+ Scanners for Quantitative (R)-[11C]verapamil, [11C]raclopride and [11C]flumazenil Brain Studies
  119. Concordance Between Cerebrospinal Fluid Biomarkers and [11C]PIB PET in a Memory Clinic Cohort
  120. Synthesis and initial preclinical evaluation of the P2X7receptor antagonist [11C]A-740003 as a novel tracer of neuroinflammation
  121. Assessment of Simplified Methods to Measure 18F-FLT Uptake Changes in EGFR-Mutated Non–Small Cell Lung Cancer Patients Undergoing EGFR Tyrosine Kinase Inhibitor Treatment
  122. Comparison of Simplified Parametric Methods for Visual Interpretation of 11C-Pittsburgh Compound-B PET Images
  123. Quantification of 18F-Fluoride Kinetics: Evaluation of Simplified Methods
  124. Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations
  125. In Vivo Imaging as a Pharmacodynamic Marker
  126. Accuracy and precision of pseudo-continuous arterial spin labeling perfusion during baseline and hypercapnia: A head-to-head comparison with 15O H2O positron emission tomography
  127. The interventricular septum in pulmonary hypertension does not show features of right ventricular failure
  128. Impact of anatomical and functional severity of coronary atherosclerotic plaques on the transmural perfusion gradient: a [15O]H2O PET study
  129. Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions
  130. Does Drug Accumulation in Bone Explain the Efficacy and Toxicity of Docetaxel in Prostate Cancer?
  131. The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer’s disease
  132. Pituitary Gland: Do Anticancer Drugs Sit in the Turkish Saddle?
  133. Accurate PET/MR Quantification Using Time of Flight MLAA Image Reconstruction
  134. Effect of Type 2 Diabetes Mellitus on Epicardial Adipose Tissue Volume and Coronary Vasomotor Function
  135. Impaired Hyperemic Myocardial Blood Flow Is Associated With Inducibility of Ventricular Arrhythmia in Ischemic Cardiomyopathy
  136. Promising potential of new generation translocator protein tracers providing enhanced contrast of arthritis imaging by positron emission tomography in a rat model of arthritis
  137. Multicenter Harmonization of 89Zr PET/CT Performance
  138. Effects of chemotherapy on the parotid and submandibular glands in head and neck cancer patients treated with chemoradiotherapy
  139. Cerebral Blood Flow and Glucose Metabolism in Appetite-Related Brain Regions in Type 1 Diabetic Patients After Treatment With Insulin Detemir and NPH Insulin
  140. Quantification of cerebral blood flow in healthy volunteers and type 1 diabetic patients: Comparison of MRI arterial spin labeling and [15O]H2O positron emission tomography (PET)
  141. Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder
  142. Activin a is associated with impaired myocardial glucose metabolism and left ventricular remodeling in patients with uncomplicated type 2 diabetes
  143. ENerGetIcs in hypertrophic cardiomyopathy: traNslation between MRI, PET and cardiac myofilament function (ENGINE study)
  144. Comparison of clinical non-commercial tools for automated quantification of myocardial blood flow using oxygen-15-labelled water PET/CT
  145. Radiation Dose of the P-Glycoprotein Tracer 11C-Laniquidar
  146. Reduction in Thyroid Perfusion After Bevacizumab Treatment
  147. Pulmonary 2‐Deoxy‐2‐[18F]‐Fluoro‐D‐Glucose Uptake is Low in Treated Patients with Idiopathic Pulmonary Arterial Hypertension
  148. Longitudinal Amyloid Imaging Using 11C-PiB: Methodologic Considerations
  149. [11C]quinidine and [11C]laniquidar PET imaging in a chronic rodent epilepsy model: Impact of epilepsy and drug-responsiveness
  150. Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [11C]docetaxel and Positron Emission Tomography
  151. Suggested pathway to assess radiation safety of 18F-labeled PET tracers for first-in-human studies
  152. Cerebral Blood Flow and Glucose Metabolism Measured With Positron Emission Tomography Are Decreased in Human Type 1 Diabetes
  153. Effect of cardiac hybrid 15O-water PET/CT imaging on downstream referral for invasive coronary angiography and revascularization rate
  154. Test-Retest Variability of Various Quantitative Measures to Characterize Tracer Uptake and/or Tracer Uptake Heterogeneity in Metastasized Liver for Patients with Colorectal Carcinoma
  155. Evaluation of strategies towards harmonization of FDG PET/CT studies in multicentre trials: comparison of scanner validation phantoms and data analysis procedures
  156. Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patients
  157. 11C-Acetate Clearance as an Index of Oxygen Consumption of the Right Myocardium in Idiopathic Pulmonary Arterial Hypertension: A Validation Study Using 15O-Labeled Tracers and PET
  158. Cancer therapy: could a novel test predict the amount of drug that reaches its target?
  159. 11C-labeled and18F-labeled PET ligands for subtype-specific imaging of histamine receptors in the brain
  160. In vivo imaging of the 18-kDa translocator protein (TSPO) with [18F]FEDAA1106 and PET does not show increased binding in Alzheimer’s disease patients
  161. Prognostic Impact of [18F]Fluorothymidine and [18F]Fluoro-D-Glucose Baseline Uptakes in Patients with Lung Cancer Treated First-Line with Erlotinib
  162. Development of [11C]erlotinib Positron Emission Tomography for In Vivo Evaluation of EGF Receptor Mutational Status
  163. Evaluation of the novel folate receptor ligand [18F]fluoro-PEG-folate for macrophage targeting in a rat model of arthritis
  164. Intervention versus standard medical treatment in patients with symptomatic occlusion of the internal carotid artery: a randomised oxygen-15 PET study
  165. Microglial activation in Alzheimer's disease: an (R)-[11C]PK11195 positron emission tomography study
  166. Positron Emission Tomography as a Method for Measuring Drug Delivery to Tumors in vivo: The Example of [11C]docetaxel
  167. Radiosynthesis and preclinical evaluation of [11C]prucalopride as a potential agonist PET ligand for the 5-HT4 receptor
  168. [11C]AF150(S), an agonist PET ligand for M1 muscarinic acetylcholine receptors
  169. Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia
  170. Amyloid and its association with default network integrity in Alzheimer's disease
  171. Hybrid Imaging Using Quantitative H215O PET and CT-Based Coronary Angiography for the Detection of Coronary Artery Disease
  172. Limbic and motor circuits involved in symmetry behavior in Tourette's syndrome
  173. Scheduling of anticancer drugs
  174. Cerebral blood flow and glucose metabolism in healthy volunteers measured using a high-resolution PET scanner
  175. Impact of molecular imaging on the diagnostic process in a memory clinic
  176. Altered GABAA Receptor Density and Unaltered Blood–Brain Barrier Transport in a Kainate Model of Epilepsy: An In Vivo Study Using 11C-Flumazenil and PET
  177. Tumor Lesion Glycolysis and Tumor Lesion Proliferation for Response Prediction and Prognostic Differentiation in Patients With Advanced Non–Small Cell Lung Cancer Treated With Erlotinib
  178. Assessment of tumour size in PET/CT lung cancer studies: PET- and CT-based methods compared to pathology
  179. Corrigendum to ‘Systolic pulmonary artery pressure and heart rate are main determinants of oxygen consumption in the right ventricular myocardium of patients with idiopathic pulmonary arterial hypertension’ [Eur J Heart Fail 2012;13:1290-1295]
  180. In vivo measurements of blood flow and bone metabolism in osteoarthritis
  181. Microglial activation in healthy aging
  182. No Evidence for Additional Blood–Brain Barrier P-Glycoprotein Dysfunction in Alzheimer's Disease Patients with Microbleeds
  183. Optimization of Supervised Cluster Analysis for Extracting Reference Tissue Input Curves in (R)-[11C]PK11195 Brain PET Studies
  184. Parametric imaging of myocardial viability using 15O-labelled water and PET/CT: comparison with late gadolinium-enhanced CMR
  185. Radiosynthesis and biological evaluation of the M1 muscarinic acetylcholine receptor agonist ligand [11C]AF150(S)
  186. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement
  187. Synthesis and preclinical evaluation of [11C]D617, a metabolite of (R)-[11C]verapamil
  188. PET in drug development
  189. Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib
  190. P-Glycoprotein Function at the Blood–Brain Barrier: Effects of Age and Gender
  191. Parametric [11C]flumazenil images
  192. [11C]Flumazenil brain uptake is influenced by the blood-brain barrier efflux transporter P-glycoprotein
  193. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET
  194. Validity of Simplified 3′-Deoxy-3′-[18F]Fluorothymidine Uptake Measures for Monitoring Response to Chemotherapy in Locally Advanced Breast Cancer
  195. Carotid artery intima-media thickness, but not coronary artery calcium, predicts coronary vascular resistance in patients evaluated for coronary artery disease
  196. In vivo quantification of striatal dopamine D2receptor occupancy by JNJ-37822681 using [11C]raclopride and positron emission tomography
  197. Blood–brain barrier P-glycoprotein function in healthy subjects and Alzheimer's disease patients: effect of polymorphisms in the ABCB1 gene
  198. Comparison of oxygen-15 PET and transcranial Doppler CO2-reactivity measurements in identifying haemodynamic compromise in patients with symptomatic occlusion of the internal carotid artery
  199. Effects of rigid and non-rigid image registration on test-retest variability of quantitative [18F]FDG PET/CT studies
  200. Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs
  201. Reproducibility of quantitative (R)-[11C]verapamil studies
  202. [11C]phenytoin revisited: synthesis by [11C]CO carbonylation and first evaluation as a P-gp tracer in rats
  203. Macrophage positron emission tomography imaging as a biomarker for preclinical rheumatoid arthritis: Findings of a prospective pilot study
  204. Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction
  205. Measurement of metabolic tumor volume: static versus dynamic FDG scans
  206. Parametric imaging of myocardial blood flow and viability using [15O]H2O and PET/CT
  207. Prediction of functional recovery after revascularization in patients with chronic ischemic myocardial dysfunction
  208. Systolic pulmonary artery pressure and heart rate are main determinants of oxygen consumption in the right ventricular myocardium of patients with idiopathic pulmonary arterial hypertension
  209. Blood–brain barrier P-glycoprotein function in Alzheimer's disease
  210. Quantitative relationship between coronary artery calcium score and hyperemic myocardial blood flow as assessed by hybrid 15O-water PET/CT imaging in patients evaluated for coronary artery disease
  211. Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non–Small Cell Lung Cancer Using 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET
  212. Right Ventricular Failure in Idiopathic Pulmonary Arterial Hypertension Is Associated With Inefficient Myocardial Oxygen Utilization
  213. Coronary risk factors and myocardial blood flow in patients evaluated for coronary artery disease: a quantitative [15O]H2O PET/CT study
  214. Quantification of the neurokinin 1 receptor ligand [11C]R116301
  215. Right Ventricular Energetics in Patients With Hypertrophic Cardiomyopathy and the Effect of Alcohol Septal Ablation
  216. Supine-exercise-induced oxygen supply to the right myocardium is attenuated in patients with severe idiopathic pulmonary arterial hypertension
  217. Impact of [18F]FDG PET imaging parameters on automatic tumour delineation: need for improved tumour delineation methodology
  218. Effects of Image Characteristics on Performance of Tumor Delineation Methods: A Test–Retest Assessment
  219. Simultaneous in vivo measurements of receptor density and affinity using [11C]flumazenil and positron emission tomography: Comparison of full saturation and steady state methods
  220. Absolute Quantification of [11C]docetaxel Kinetics in Lung Cancer Patients Using Positron Emission Tomography
  221. Widespread and Prolonged Increase in (R)-11C-PK11195 Binding After Traumatic Brain Injury
  222. Effects of alcohol septal ablation on coronary microvascular function and myocardial energetics in hypertrophic obstructive cardiomyopathy
  223. Comment on Cho et al.: Usefulness of FDG PET/CT in determining benign from malignant endobronchial obstruction
  224. Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies
  225. Early Prediction of Nonprogression in Advanced Non–Small-Cell Lung Cancer Treated With Erlotinib By Using [18F]Fluorodeoxyglucose and [18F]Fluorothymidine Positron Emission Tomography
  226. Effects of Pacing Rates on Global and Regional Myocardial Blood Flow
  227. Relation of Coronary Microvascular Dysfunction in Hypertrophic Cardiomyopathy to Contractile Dysfunction Independent from Myocardial Injury
  228. Feasibility of subendocardial and subepicardial myocardial perfusion measurements in healthy normals with 15O-labeled water and positron emission tomography
  229. Parametric Images of Myocardial Viability Using a Single 15O-H2O PET/CT Scan
  230. Automatic generation of absolute myocardial blood flow images using [15O]H2O and a clinical PET/CT scanner
  231. Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis
  232. (R)-[11C]Verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus
  233. Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men
  234. Increased cerebral (R)-[11C]PK11195 uptake and glutamate release in a rat model of traumatic brain injury: a longitudinal pilot study
  235. Reappraisal of a single-tissue compartment model for estimation of myocardial oxygen consumption by [11C]acetate PET
  236. 18F-FDG PET as a Tool to Predict the Clinical Outcome of Infliximab Treatment of Rheumatoid Arthritis: An Explorative Study
  237. Myocardial Oxygen Extraction Fraction Measured Using Bolus Inhalation of 15O-Oxygen Gas and Dynamic PET
  238. Carbon-11 Labeled Tracers for In Vivo Imaging of P-Glycoprotein Function: Kinetics, Advantages and Disadvantages
  239. Quantitative Parametric Perfusion Images Using 15O-Labeled Water and a Clinical PET/CT Scanner: Test–Retest Variability in Lung Cancer
  240. Day-to-Day Test–Retest Variability of CBF, CMRO2, and OEF Measurements Using Dynamic 15O PET Studies
  241. Impact of Liver Fat on Type 2 Diabetes: Perfusion and Metabolism
  242. Dementia Mimicking Alzheimer's Disease Owing to a Tau Mutation: CSF and PET Findings
  243. Effects of Hepatic Triglyceride Content on Myocardial Metabolism in Type 2 Diabetes
  244. Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [11C]PIB and [18F]FDDNP PET images
  245. Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients
  246. Image Derived Input Functions: Effects of Motion on Tracer Kinetic Analyses
  247. Partial volume correction strategies for quantitative FDG PET in oncology
  248. Risk stratification for ventricular arrhythmias in ischaemic cardiomyopathy: the value of non-invasive imaging
  249. Low-Dose Quantitative Myocardial Blood Flow Imaging Using 15O-Water and PET Without Attenuation Correction
  250. Cardiac PET-CT: advanced hybrid imaging for the detection of coronary artery disease
  251. Pharmaceutical preparation of oxygen-15 labelled molecular oxygen and carbon monoxide gasses in a hospital setting
  252. Determinants of myocardial energetics and efficiency in symptomatic hypertrophic cardiomyopathy
  253. Diabetic cardiomyopathy in Zucker diabetic fatty rats: the forgotten right ventricle
  254. Simplified parametric methods for [18F]FDDNP studies
  255. Potential of [11C]acetate for measuring myocardial blood flow: Studies in normal subjects and patients with hypertrophic cardiomyopathy
  256. Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment
  257. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0
  258. Reference Tissue Models and Blood–Brain Barrier Disruption: Lessons from (R)-[11C]PK11195 in Traumatic Brain Injury
  259. Reduced parahippocampal and lateral temporal GABAA-[11C]flumazenil binding in major depression: preliminary results
  260. In vivo Validation of Reconstruction-Based Resolution Recovery for Human Brain Studies
  261. Downregulation of 18F-FDG Uptake in PET as an Early Pharmacodynamic Effect in Treatment of Non–Small Cell Lung Cancer with the mTOR Inhibitor Everolimus
  262. Arterial Spin Labeling Perfusion MRI at Multiple Delay Times: A Correlative Study with H215O Positron Emission Tomography in Patients with Symptomatic Carotid Artery Occlusion
  263. Repeatability of 18F-FDG PET in a Multicenter Phase I Study of Patients with Advanced Gastrointestinal Malignancies
  264. A method to measure PET scatter fractions for daily quality control
  265. Relationship of Cerebrospinal Fluid Markers to11C-PiB and18F-FDDNP Binding
  266. Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats
  267. Altered myocardial substrate metabolism is associated with myocardial dysfunction in early diabetic cardiomyopathy in rats: studies using positron emission tomography
  268. Off-line motion correction methods for multi-frame PET data
  269. Hemodynamic changes in ipsi- and contralateral cerebral arterial territories after carotid endarterectomy using positron emission tomography
  270. Coronary microvascular resistance: methods for its quantification in humans
  271. Test-retest variability of quantitative [11C]PIB studies in Alzheimer’s disease
  272. Pioglitazone Improves Cardiac Function and Alters Myocardial Substrate Metabolism Without Affecting Cardiac Triglyceride Accumulation and High-Energy Phosphate Metabolism in Patients With Well-Controlled Type 2 Diabetes Mellitus
  273. HRRT Versus HR+ Human Brain PET Studies: An Interscanner Test–Retest Study
  274. Evaluation of Tracer Kinetic Models for Analysis of [18F]FDDNP Studies
  275. First Evaluation of [11C]R116301 as an In Vivo Tracer of NK1 Receptors in Man
  276. No Signs of Metabolic Hyperactivity in Patients With Unilateral Condylar Hyperactivity: An In Vivo Positron Emission Tomography Study
  277. Comparison of transcranial Doppler ultrasonography and positron emission tomography using a three-dimensional template of the middle cerebral artery
  278. Kinetic models for analysing myocardial [11C]palmitate data
  279. Detection of Alzheimer Pathology In Vivo Using Both 11C-PIB and 18F-FDDNP PET
  280. Changes in GABAAreceptor properties in amygdala kindled animals: In vivo studies using [11C]flumazenil and positron emission tomography
  281. Accuracy of 3-Dimensional Reconstruction Algorithms for the High-Resolution Research Tomograph
  282. Image derived input functions for dynamic High Resolution Research Tomograph PET brain studies
  283. Quantification of (R)-[11C]PK11195 binding in rheumatoid arthritis
  284. Image-derived input functions for PET brain studies
  285. Microglia Activation in Recent-Onset Schizophrenia: A Quantitative (R)-[11C]PK11195 Positron Emission Tomography Study
  286. Noninvasive imaging of macrophages in rheumatoid synovitis using11C-(R)-PK11195 and positron emission tomography
  287. Peripheral metabolism of [18F]FDDNP and cerebral uptake of its labelled metabolites
  288. Impact of wavelet based denoising of [C11](R)-PK11195 time activity curves on accuracy and precision of kinetic analysis
  289. Reproducibility of quantitative 18F-3′-deoxy-3′-fluorothymidine measurements using positron emission tomography
  290. Reproducibility of Tumor Perfusion Measurements Using 15O-Labeled Water and PET
  291. Individualized Treatment Planning in Oncology: Role of PET and Radiolabelled Anticancer Drugs in Predicting Tumour Resistance
  292. Implementation of physiological gating on the high resolution research tomograph
  293. Performance of a modified supervised cluster algorithm for extracting reference region input functions from (R)-[<sup>11</sup>C]PK11195 brain PET studies
  294. Δ9-Tetrahydrocannabinol Induces Dopamine Release in the Human Striatum
  295. Blood Flow and Glucose Metabolism in Stage IV Breast Cancer: Heterogeneity of Response During Chemotherapy
  296. Blood–brain barrier P-glycoprotein function is not impaired in early Parkinson's disease
  297. Simplified parametric methods for [11C]PIB studies
  298. [18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study
  299. Gap Filling Strategies for 3-D-FBP Reconstructions of High-Resolution Research Tomograph Scans
  300. Bone Metabolism after Total Hip Revision Surgery with Impacted Grafting: Evaluation using H2 15O and [18F]fluoride PET; A Pilot Study
  301. Peroperative Neuromonitoring during Carotid Endarterectomy in Relation to Preoperative Positron Emission Tomography Findings
  302. Comparison of 3D-OP-OSEM and 3D-FBP reconstruction algorithms for High-Resolution Research Tomograph studies: effects of randoms estimation methods
  303. A new rat model of human breast cancer for evaluating efficacy of new anti-cancer agents in vivo
  304. Stroke volume measurements with first-pass dynamic positron emission tomography: Comparison with cardiovascular magnetic resonance
  305. Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy
  306. Partial volume corrected image derived input functions for dynamic PET brain studies: Methodology and validation for [11C]flumazenil
  307. Synthesis of 2-(1,1-dicyanopropen-2-yl)-6-(2-[18F]-fluoroethyl)-methylamino-naphthalene ([18F]FDDNP)
  308. Quantitative Issues in Response Measurement by PET
  309. Imaging trauma in vivo: GABAA benzodiazepine receptor binding
  310. [11C]Docetaxel and Positron Emission Tomography for Noninvasive Measurements of Docetaxel Kinetics
  311. Impact of attenuation correction strategies on the quantification of High Resolution Research Tomograph PET studies
  312. Microvascular Function in Viable Myocardium After Chronic Infarction Does Not Influence Fractional Flow Reserve Measurements
  313. Comparison of Plasma Input and Reference Tissue Models for Analysing [11C]flumazenil Studies
  314. Assessment of intravascular and extravascular mechanisms of myocardial perfusion abnormalities in obstructive hypertrophic cardiomyopathy by myocardial contrast echocardiography
  315. 2-Deoxy-2-[F-18]fluoro-D-glucose Joint Uptake on Positron Emission Tomography Images: Rheumatoid Arthritis Versus Osteoarthritis
  316. Peripheral metabolism of (R)-[11C]verapamil in epilepsy patients
  317. Reduced GABAA benzodiazepine receptor binding in veterans with post-traumatic stress disorder
  318. Monitoring Response to Radiotherapy in Human Squamous Cell Cancer Bearing Nude Mice: Comparison of 2′-deoxy-2′-[18F]fluoro-d-glucose (FDG) and 3′-[18F]fluoro-3′-deoxythymidine (FLT)
  319. Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
  320. Hyperaemic microvascular resistance is not increased in viable myocardium after chronic myocardial infarction
  321. SPM analysis of parametric (R)-[11C]PK11195 binding images: Plasma input versus reference tissue parametric methods
  322. Evaluation of Reference Regions for (R)-[11C]PK11195 Studies in Alzheimer's Disease and Mild Cognitive Impairment
  323. Accuracy of 3D acquisition mode for myocardial FDG PET studies using a BGO-based scanner
  324. Evaluation of Methods for Generating Parametric (R)-[11C]PK11195 Binding Images
  325. Myocardial Energetics and Efficiency
  326. Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner
  327. Diagnostic and clinical perspectives of fusion imaging in cardiology: is the total greater than the sum of its parts?
  328. Quantification of Dopamine Transporter Binding Using [18F]FP-β-CIT and Positron Emission Tomography
  329. Different brain effects during chronic and acute sacral neuromodulation in urge incontinent patients with implanted neurostimulators
  330. FDG PET as a predictor of response to resynchronisation therapy in patients with ischaemic cardiomyopathy
  331. Imaging P-glycoprotein at the human blood-brain barrier
  332. Regional heterogeneity of resting perfusion in hypertrophic cardiomyopathy is related to delayed contrast enhancement but not to systolic function: A PET and MRI study
  333. Optimization algorithms and weighting factors for analysis of dynamic PET studies
  334. Does Myocardial Fibrosis Hinder Contractile Function and Perfusion in Idiopathic Dilated Cardiomyopathy? PET and MR Imaging Study
  335. Radiosynthesis and biodistribution of a histamine H3 receptor antagonist 4-[3-(4-piperidin-1-yl-but-1-ynyl)-[11C]benzyl]-morpholine: evaluation of a potential PET ligand
  336. How should we analyse FDG PET studies for monitoring tumour response?
  337. Evaluation of Tracer Kinetic Models for Quantification of P-Glycoprotein Function using (R)-[11C]Verapamil and PET
  338. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[11C]verapamil and positron emission tomography
  339. Impact of Scar on Water-Perfusable Tissue Index in Chronic Ischemic Heart Disease
  340. Performance of Immuno–Positron Emission Tomography with Zirconium-89-Labeled Chimeric Monoclonal Antibody U36 in the Detection of Lymph Node Metastases in Head and Neck Cancer Patients
  341. Evaluation of Reference Tissue Models for the Analysis of [11C](R)-PK11195 Studies
  342. Quantification of Myocardial Perfusion Using Intravenous Myocardial Contrast Echocardiography in Healthy Volunteers: Comparison with Positron Emission Tomography
  343. Quantitative Experimental Comparison of HRRT versus HR+ PET Brain Studies
  344. Asymptomatic Carotid Artery Stenosis: Past, Present and Future
  345. Editorial
  346. Imaging approaches for monitoring chemotherapy
  347. Imaging studies for evaluating gene therapy in translational research
  348. Imaging studies in drug development: Parkinson's disease
  349. Imaging technologies in drug development: Anxiety and depression
  350. PET studies in drug development: Methodological considerations
  351. The enabling technologies needed for PET-based molecular imaging to support drug development
  352. Prognostic Relevance of Response Evaluation Using [18F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Patients With Locally Advanced Non–Small-Cell Lung Cancer
  353. Measurement of left ventricular volumes and function with O-15–labeled carbon monoxide gated positron emission tomography: Comparison with magnetic resonance imaging
  354. Population Pharmacokinetic Analysis for Simultaneous Determination of B max and K D In Vivo by Positron Emission Tomography
  355. Population plasma pharmacokinetics of 11C-flumazenil at tracer concentrations
  356. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial
  357. Evaluation of Basis Function and Linear Least Squares Methods for Generating Parametric Blood Flow Images Using 15O-Water and Positron Emission Tomography
  358. Standardised FDG uptake: A prognostic factor for inoperable non-small cell lung cancer
  359. Enhancement of perfusion reserve by cardiac resynchronization therapy
  360. Optimizing an online SPE–HPLC method for analysis of (R)-[11C]1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide [(R)-[11C]PK11195] and its metabolites in humans
  361. Development of a Tracer Kinetic Plasma Input Model for (R)-[11C]PK11195 Brain Studies
  362. Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood–brain barrier: kinetics and metabolism in the rat
  363. Memory Performance and the Growth Hormone/Insulin-Like Growth Factor Axis in Elderly: A Positron Emission Tomography Study
  364. Amygdala activity in obsessive-compulsive disorder with contamination fear: a study with oxygen-15 water positron emission tomography
  365. Neurophysiological correlates of habituation during exposure in spider phobia
  366. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial
  367. Radiosynthesis of[11C]docetaxel
  368. Transport across the blood-brain barrier: stereoselectivity and PET-tracers
  369. Effects of Cardiac Resynchronization Therapy on Myocardial Perfusion Reserve
  370. Role of human and animal PET studies in drug development
  371. Correction for emission contamination in transmission scans for the high resolution research tomograph
  372. 18F-2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography in Staging of Locally Advanced Breast Cancer
  373. Optimization of attenuation correction for positron emission tomography studies of thorax and pelvis using count-based transmission scans
  374. The perfusable tissue index: a marker of myocardial viability
  375. Use of an in-field-of-view shield to improve count rate performance of the single crystal layer high-resolution research tomograph PET scanner for small animal brain scans
  376. 18 FDG positron emission tomography versus 67 Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin's lymphoma
  377. (R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation
  378. Correction methods for missing data in sinograms of the HRRT PET scanner
  379. Effects of attenuation correction and reconstruction method on PET activation studies
  380. Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods
  381. Attenuation correction of PET activation studies in the presenceof task-related motion
  382. The value of positron emission tomography for monitoring response to radiotherapy in head and neck cancer
  383. Experimental evaluation of iterative reconstruction versus filtered back projection for 3D [15O]water PET activation studies using statistical parametric mapping analysis
  384. How morphometric analysis of metastatic load predicts the (un)usefulness of PET scanning: the case of lymph node staging in melanoma
  385. Myocardial viability inchronic ischemic heart disease
  386. Measuring [18F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods
  387. Quantitative assessment of fracture healing using positron emission tomography
  388. Characterization of a single LSO crystal layer High Resolution Research Tomograph
  389. Radioligand studies: imaging and quantitative analysis
  390. Determinants of Diagnostic Performance Of [F-18]Fluorodeoxyglucose Positron Emission Tomography for Axillary Staging in Breast Cancer
  391. Matching PET and CT scans of the head and neck area: Development of method and validation
  392. Use of arterialised venous instead of arterial blood for measurement of myocardial glucose metabolism during euglycaemic-hyperinsulinaemic clamping
  393. Biologic Correlates of 18Fluorodeoxyglucose Uptake in Human Breast Cancer Measured by Positron Emission Tomography
  394. Fully automated high yield synthesis of (R)- and (S)-[11C]verapamil for measuring P-glycoprotein function with positron emission tomography
  395. The Use of PET in Evaluating Tumor Response and Cancer Therapy
  396. Measurement of Tumor Response Using [18F]-2-Fluoro-2-Deoxy-D-Glucose and Positron-Emission Tomography
  397. Dipyridamole-induced increased glucose uptake in patients with single-vessel coronary artery disease assessed with PET
  398. PET/SPECT: functional imaging beyond flow
  399. Carbon-11 acetate as a tracer of myocardial oxygen consumption
  400. Pulmonary β adrenoceptor density in arrhythmogenic right ventricular cardiomyopathy and idiopathic tachycardia
  401. Characteristics of a new fully programmable blood sampling device for monitoring blood radioactivity during PET
  402. On the use of the injection catheter for venous blood sampling in quantitative FDG PET studies
  403. Quantitative analysis of [carbonyl-11C]WAY-100635 PET studies
  404. Monitoring response to therapy in cancer using [ 18 F]-2-fluoro-2-deoxy- d -glucose and positron emission tomography: an overview of different analytical methods
  405. Abnormalities of Cardiac Sympathetic Innervation in Arrhythmogenic Right Ventricular Cardiomyopathy
  406. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations
  407. On the use of image-derived input functions in oncological fluorine-18 fluorodeoxyglucose positron emission tomography studies
  408. Transmural myocardial blood flow distribution in hypertrophic cardiomyopathy and effect of treatment
  409. Tracer Kinetic Modeling of the 5-HT1AReceptor Ligand [carbonyl-11C]WAY-100635 for PET
  410. Measurement of myocardial blood flow with oxygen-15 labelled water: comparison of different administration protocols
  411. Cardiac sympathetic innervation in patients with idiopathic right ventricular outflow tract tachycardia
  412. Myocardial Presynaptic and Postsynaptic Autonomic Dysfunction in Hypertrophic Cardiomyopathy
  413. Evaluation of compartmental and spectral analysis models of [/sup 18/F]FDG kinetics for heart and brain studies with PET
  414. Pathophysiological Mechanisms of Chronic Reversible Left Ventricular Dysfunction due to Coronary Artery Disease (Hibernating Myocardium)
  415. Parametric Imaging of Ligand-Receptor Binding in PET Using a Simplified Reference Region Model
  416. In vivo saturation kinetics of two dopamine transporter probes measured using a small animal positron emission tomography scanner
  417. Calculation of single detector efficiencies and extension of the normalization sinogram in PET
  418. Three-dimensional performance of a small-diameter positron emission tomograph
  419. Evaluation in rat of RS-79948-197 as a potential PET ligand for central α2-adrenoceptors
  420. Simplified Reference Tissue Model for PET Receptor Studies
  421. Cardiac and skeletal muscle insulin resistance in patients with coronary heart disease. A study with positron emission tomography.
  422. Noninvasive Quantification of Regional Myocardial Metabolic Rate of Oxygen by 15 O 2 Inhalation and Positron Emission Tomography
  423. Linear dimension reduction of sequences of medical images: III. Factor analysis in signal space
  424. The potential of high-resolution positron emission tomography to monitor striatal dopaminergic function in rat models of disease.
  425. Development of central 5-HT2A receptor radioligands for PET: Comparison of [3H]RP 62203 and [3H]SR 46349B kinetics in rat brain
  426. Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11C]WAY-100635
  427. Noninvasive Quantification of rCBF Using Positron Emission Tomography
  428. The development of in vivo tracer methods to obtain new information about human disease: a study of the hallucinating brain
  429. The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography
  430. Pathophysiology of Chronic Left Ventricular Dysfunction
  431. Measurement of liver blood flow using oxygen-15 labelled water and dynamic positron emission tomography: Limitations of model description
  432. Comparison of Methods for Analysis of Clinical [11C]Raclopride Studies
  433. Hyperdynamic performance of remote myocardium in acute infarction
  434. Linear dimension reduction of sequences of medical images: I. Optimal inner products
  435. Linear dimension reduction of sequences of medical images: II. Direct sum decomposition
  436. Effect of L-dopa and 6-hydroxydopamine lesioning on [11C]raclopride binding in rat striatum, quantified using PET
  437. First delineation of 5-HT1A receptors in human brain with PET and [11C]WAY-100635
  438. Effect of tissue heterogeneity on quantification in positron emission tomography
  439. Benzodiazepine-GABAA Receptor Binding During Absence Seizures
  440. The design and physical characteristics of a small animal positron emission tomograph
  441. Benzodiazepine-GABAA Receptors in Idiopathic Generalized Epilepsy Measured with [11C]Flumazenil and Positron Emission Tomography
  442. Benzodiazepine Receptor Quantification in vivo in Humans Using [11C]Flumazenil and PET: Application of the Steady-State Principle
  443. Evaluation of [O-methyl-3H]WAY-100635 as an in vivo radioligand for 5-HT1A receptors in rat brain
  444. Dosimetry of intravenously administered oxygen-15 labelled water in man: a model based on experimental human data from 21 subjects
  445. PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette's syndrome.
  446. Changes in global cerebral blood flow in humans: effect on regional cerebral blood flow during a neural activation task.
  447. Diffuse reduction of myocardial beta-adrenoceptors in hypertrophic cardiomyopathy: A study with positron emission tomography
  448. Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and11C-raclopride
  449. Comparison of regional myocardial blood flow in syndrome X and one-vessel coronary artery disease
  450. Vasodilator reserve in collateral-dependent myocardium as measured by positron emission tomography
  451. Ageing and brain: clinical perspectives of PET
  452. The significance of a dipyridamole induced 99mTc-MIBI perfusion abnormality on single photon emission tomography: a quantitative validation with labelled water and positron emission tomography
  453. Evaluation of S-[11C]citalopram as a radioligand for in vivo labelling of 5-hydroxytryptamine uptake sites
  454. Quantification of in vivo binding of [3H]RX 821002 in rat brain: Evaluation as a radioligand for central α2-adrenoceptors
  455. Positron emission tomography for tumour assessment
  456. Quantitation of Carbon-11-labeled raclopride in rat striatum using positron emission tomography
  457. Low oxygen extraction fraction in tumours measured with the oxygen-15 steady state technique: effect of tissue heterogeneity
  458. A new strategy for the assessment of viable myocardium and regional myocardial blood flow using 15O-water and dynamic positron emission tomography.
  459. Monitoring by PET of macrophage accumulation in brain after ischaemic stroke
  460. In vivo Measurement of the Volume of Distribution of Water in Cerebral Grey Matter: Effects on the Calculation of Regional Cerebral Blood Flow
  461. Measurement of regional myocardial blood flow using C 15 O 2 and positron emission tomography: comparison of tracer models
  462. Positron emission tomography
  463. Dipyridamole vasodilator response after human orthotopic heart transplantation: Quantification by oxygen-15-labeled water and positron emission tomography
  464. Regional cerebral blood flow during volitional breathing in man.
  465. Measurement of Cerebral Monoamine Oxidase B Activity Using L-[11C]Deprenyl and Dynamic Positron Emission Tomography
  466. Noninvasive quantification of regional myocardial blood flow in coronary artery disease with oxygen-15-labeled carbon dioxide inhalation and positron emission tomography.
  467. Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327
  468. Quantitative measurement of monoclonal antibody distribution and blood flow using positron emission tomography and124iodine in patients with breast cancer
  469. Combination of Dynamic and Integral Methods for Generating Reproducible Functional CBF Images
  470. The Relationship between Global and Local Changes in PET Scans
  471. Inhibition of brain monoamine oxidase-B by Ro19-6327 — in vivo measurerment using positron emission tomography
  472. CEREBRAL BLOOD FLOW, BLOOD VOLUME AND OXYGEN UTILIZATION
  473. EEC concerted action on cellular degeneration and regeneration studied with PET
  474. Use of PET Methods for Measurement of Cerebral Energy Metabolism and Hemodynamics in Cerebrovascular Disease
  475. The colour centre in the cerebral cortex of man
  476. The C15O2 Build-up Technique to Measure Regional Cerebral Blood Flow and Volume of Distribution of Water
  477. Stability of Arterial Concentrations during Continuous Inhalation of C15O2 and 15O2 and the Effects on Computed Values of CBF and CMRO2
  478. Positron emission tomography andin vivo measurements of tumour perfusion and oxygen utilisation
  479. Correction for Intravascular Activity in the Oxygen-15 Steady-State Technique is Independent of the Regional Hematocrit
  480. Measurement of Glucose Utilisation with [18F]2-Fluoro-2-Deoxy-D-Glucose: A Comparison of Different Analytical Methods
  481. Rubidium-82 Myocardial Uptake and Extraction After Transient Ischemia
  482. Measurement of regional cerebral blood flow, blood volume and oxygen metabolism in patients with sickle cell disease using positron emission tomography.
  483. Studies on regional cerebral haematocrit and blood flow in patients with cerebral tumours using positron emission tomography
  484. A comparison between regional cerebral blood flow measurements obtained in human subjects using11C-methylalbumin microspheres, the C15O2steady-state method, and positron emission tomography
  485. Glucose Transport across the Blood—Brain Barrier in Normal Human Subjects and Patients with Cerebral Tumours Studied Using [11C]3-O-Methyl-D-Glucose and Positron Emission Tomography
  486. Measurement of blood flow, oxygen utilisation, oxygen extraction ratio, and fractional blood volume in human brain tumours and surrounding oedematous tissue
  487. Influence of Intravascular Activity on the Determination of Blood Flow and Oxygen Extraction in Normal and Ulcerated Legs Using the 15O Steady-State Technique and Positron Emission Tomography
  488. A Method to Quantitate the Fractional Extraction of Rubidium-82 across the Blood—Brain Barrier Using Positron Emission Tomography
  489. Quantitative Measurement of Blood—Brain Barrier Permeability Using Rubidium-82 and Positron Emission Tomography
  490. In vivo Measurement of Regional Cerebral Haematocrit Using Positron Emission Tomography
  491. Measurement of Regional Cerebral pH in Human Subjects Using Continuous Inhalation of 11CO2 and Positron Emission Tomography
  492. Measurement of Cerebral Blood Flow Using Bolus Inhalation of C15O2 and Positron Emission Tomography: Description of the Method and its Comparison with the C15O2 Continuous Inhalation Method
  493. POSITRON EMISSION TOMOGRAPHY FOR IN-VIVO MEASUREMENT OF REGIONAL BLOOD FLOW, OXYGEN UTILISATION, AND BLOOD VOLUME IN PATIENTS WITH BREAST CARCINOMA
  494. Positron emission tomography of the brain: Measurement of regional cerebral function in man
  495. Positron emission tomography of the brain: new possibilities for the investigation of human cerebral pathophysiology
  496. Correction for the Presence of Intravascular Oxygen-15 in the Steady-State Technique for Measuring Regional Oxygen Extraction Ratio in the Brain: 2. Results in Normal Subjects and Brain Tumour and Stroke Patients
  497. Correction for the Presence of Intravascular Oxygen-15 in the Steady-State Technique for Measuring Regional Oxygen Extraction Ratio in the Brain: 1. Description of the Method
  498. In vivo measurements of regional cerebral blood flow and blood volume in patients with brain tumours using positron emission tomography
  499. A Statistical Study of the Steady State Technique for Measuring Regional Cerebral Blood Flow and Oxygen Utilisation Using 15O
  500. Measurement of regional cerebral blood flow and oxygen utilisation in patients with cerebral tumours using 15O and positron emission tomography: Analytical techniques and preliminary results
  501. Extraction of Water Labeled With Oxygen 15 During Single-Capillary Transit
  502. A Theoretical Study of the Steady-State Model for Measuring Regional Cerebral Blood Flow and Oxygen Utilisation Using Oxygen-15
  503. High Resolution PET Imaging Characteristics of /sup68/Ga, /sup124/I and /sup 89/Zr Compared to /sup 18/F
  504. The Second Generation HRRT - a Multi Centre Scanner Performance Investigation